T. Rowe Price Investment Management
CGON icon

T. Rowe Price Investment Management’s CG Oncology CGON Stock Holding History

T. Rowe Price Investment Management’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$470M Sell
6,616,899
-103,490
-2% -$6.77M 0.31% 79
2026
Q1 		$455M Buy
6,720,389
+6,297,797
+1,490% +$357M 0.31% 86
2025
Q4 		$17.5M Buy
+422,592
New +$17.5M 0.01% 513
2024
Q3 		– Sell
-66,596
Closed -$2.1M – 629
2024
Q2 		$2.1M Sell
66,596
-642,115
-91% -$22.3M ﹤0.01% 587
2024
Q1 		$31.1M Buy
+708,711
New +$28.9M 0.02% 459

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management's CGON Position: Q2 2026 in Review

T. Rowe Price Investment Management reduced its CG Oncology (CGON) stake by 1.5% in Q2 2026, selling an estimated $6.77M and leaving 6,616,899 shares worth $470M. The position accounts for 0.31% of the portfolio, ranked #79.

T. Rowe Price Investment Management first reported a position in CGON in Q1 2024 and has held it in 5 quarters since. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • T. Rowe Price Investment Management held 6,616,899 shares of CG Oncology worth $470M as of Q2 2026.
  • T. Rowe Price Investment Management sold 103,490 CG Oncology shares in Q2 2026, an estimated $6.77M.
  • CG Oncology made up 0.31% of T. Rowe Price Investment Management's portfolio in Q2 2026, its #79 holding.
  • T. Rowe Price Investment Management first reported a position in CG Oncology in Q1 2024 and has held it in 5 quarters since.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.